Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Stanley Black & Decker, Inc. (SWK) Price & Performance

Inovio Pharmaceuticals IncTrade
Stanley Black & Decker, Inc.Trade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Stanley Black & Decker, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Stanley Black & Decker, Inc. trades at $88.57 (market cap $13.47B). The key difference: Stanley Black & Decker, Inc. is far larger — about 120.1× Inovio Pharmaceuticals Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Stanley Black & Decker, Inc. for 62 Days on average.

INOSWK
Market Cap
$112.19M$13.47B
Volume
3,201,2782,859,744
Sector
HealthIndustrials
52-Week High
$2.60$104.00
52-Week Low
$0.66$62.12
Typical Hold Time
43 Days62 Days
Enterprise Value
$83.51M$17.63B
Dividend Yield
—3.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.

Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.

Stanley Black & Decker, Inc.

Stanley Black & Decker (SWK) trades at $89.17, up 0.97% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and projected 2026 net income margin rising to 4.06%. Valuation metrics appear reasonable with P/E of 21.8 and P/S of 0.89, while analyst consensus leans neutral with 43% buy ratings and $93 price target.

SWK presents a mixed outlook with strong brand positioning and margin improvement initiatives offset by technical weakness and competitive pressures. The stock offers value characteristics with dividend stability but faces execution risks in achieving projected earnings growth. Near-term direction will depend on Q3 2026 results due November 4, 2026.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INO
96% Buy4% Sell
Avg holding period · 43 Days
SWK

No sentiment data available yet.

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →

About Stanley Black & Decker, Inc.

Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.

Read more on SWK →